Urothelkarzinom

Nicht-muskelinvasives Blasenkarzinom

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Ausführliche Informationen


Nicht-muskelinvasives Blasenkarzinom

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemo-therapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (THOR2)

Ausführliche Informationen


Muskelinvasives Blasenkarzinom

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post-Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC

Ausführliche Informationen

 


Muskelinvasives Blasenkarzinom

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Ausführliche Informationen


Metastasiertes Urothelkarzinom

A Study of Enfortumab-Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial cancer (EV-302)

Ausführliche Informationen


Metastasiertes Urothelkarzinom mUC nach Chemotherapie XL-092

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen


Metastasiertes Urothelkarzinom mUC nach Chemotherapie
XL-092 und Immuntherapie

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen


Metastasiertes Urothelkarzinom mUC nach Immuntherapie
Monotherapie mit XL-092

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen